Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
160 Health InternationalFRA:O66 -5.84%8 Debt-to-EBITDA is -2.59 as of Dec. 2025. GuruFocus rates FRA:O66 with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 91 Medical Distribution companies, 160 Health International ranks worse than 1098900% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for 160 Health International's Debt-to-EBITDA or its related term are showing as below:
FRA:O66'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.88 Med: -0.86 Max: -0.37
Current: -3.88
During the past 4 years, the highest Debt-to-EBITDA Ratio of 160 Health International was -0.37. The lowest was -3.88. And the median was -0.86.
FRA:O66's Debt-to-EBITDA is ranked worse than 100% of 91
companies
in the Medical Distribution industry
Industry Median: 2.32
vs FRA:O66: -3.88
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
160 Health International Debt-to-EBITDA Related Terms
160 Health International Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:O66 vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, 160 Health International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
160 Health International Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, 160 Health International's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where 160 Health International's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
160 Health International (FRA:O66) has a Debt-to-EBITDA of -2.59 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on 160 Health International. According to the industry distribution chart, 160 Health International ranks #999999 out of 91 companies in the Medical Distribution industry.
Is 160 Health International's Debt-to-EBITDA too high?
160 Health International's current Debt-to-EBITDA is -2.59. Based on the distribution chart, 160 Health International ranks #999999 out of 91 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, 160 Health International has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does 160 Health International's Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, 160 Health International ranks #999999 out of 91 companies for Debt-to-EBITDA. This places 160 Health International in the lower half of its industry. The industry median Debt-to-EBITDA is 2.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.32, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on 160 Health International. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 160 Health International's current Debt-to-EBITDA is -2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 160 Health International stock overvalued right now?
160 Health International (FRA:O66) has a current Debt-to-EBITDA of -2.59. The current Debt-to-EBITDA is -2.59. 160 Health International's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For 160 Health International (FRA:O66), the current Debt-to-EBITDA is -2.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
160 Health International Ltd is an experienced pharmaceutical and healthcare product wholesaler and a digital healthcare integrated service provider in China. The company offers a wide assortment of high-quality pharmaceutical and healthcare products under both wholesale and retail models, to address a spectrum of customer needs. In addition, through its online healthcare and wellness service platform, Healthcare 160 Platform. It also provide digital healthcare and wellness solutions, empowering each Platform Participants, including business customers, medical and healthcare institutions, medical professionals, individual users, and third-party merchants, throughout the healthcare value chain and driving the digital transformation of China's healthcare and wellness industry.
8GF Score
Get the complete analysis for FRA:O66
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O66 has been successfully added to your 
